Alpha MOS announced last night that it had concluded, on schedule, the second clinical study of its non-invasive breath glucose monitoring device.

According to the company, the study - which was launched at the end of 2021 by Toulouse University Hospital and involved 130 patients with type 2 diabetes - met its objectives.

In a press release, Alpha Mos says it not only established the successful functional test of the system, but also confirmed patient interest in the new device, developed by its medtech subsidiary BOYDSense.

Euroland's analysts commented this morning: "This information is a further step towards the design of a complete breath glucose monitoring device and its launch on the market".

The research department maintains its buy recommendation on the share, with an unchanged target price of 30 euros.

Copyright (c) 2023 CercleFinance.com. All rights reserved.